Live webinar: Preoperative immunotherapy in early stage TNBC: Are we doing it right?
Supported by MSD
Thursday, December 1, 2022
19:00 (7:00PM) (AEDT)
|Chairperson||Prof Christobel Saunders|
|7.05-7.25pm||Nodal positivity in early-stage triple-negative breast cancer:
Implications for preoperative immunotherapy (20 mins)
Prof Christobel Saunders
|7.25-7.40pm||What are we doing in practice?
Early-stage triple-negative breast cancer case and referral discussion (15 mins)
Prof Christobel Saunders, A/Prof Nicole McCarthy & A/Prof Andrew Redfern
|7.40-7.55pm||Q and A|
|7.55-8.00pm||Summary and close
Prof Christobel Saunders
MEET THE FACULTY
|Prof Christobel Saunders||A/Prof Nicole McCarthy||A/Prof Andrew Redfern|
Professor Christobel Saunders AO, MB BS, FRCS, FRACS, FAAHMS is the James Stewart Chair of Surgery and Head of the Department of Surgery at the University of Melbourne (The Royal Melbourne Hospital precinct) and consultant surgeon in the Department of General Surgery at the Royal Melbourne Hospital and Peter MacCallum Cancer Institute. Previously she was Professor of Surgery for 19 years at the University of Western Australia and consultant surgeon at Fiona Stanley and St John of God Hospitals in Perth and head of breast cancer research at SJOG. She was the inaugural Chair of the WA Health Service Provider PathWest Laboratory Medicine (the state-wide pathology and forensic biology provider with around 2500 staff and an annual budget of $360m) until her move to Victoria last December and remains on the Board. She is also Chief Medical Officer to the multi-award winning biomedical start-up OncoRes. Up until last year she was a long-standing member of the CRC Advisory Committee (Commonwealth Dept. Industry, Innovation & Science).
Christobel is internationally recognised as one of Australia’s most prominent research-orientated cancer surgeons. She has substantially contributed to cancer research including clinical trials of new treatments, psychosocial, translational and health services research. She has performed research for >30 years evaluating the efficacy and utility of therapy for early breast cancer, and has chaired the development of the Cancer Australia Early Breast Cancer Guidelines, Optimal Care Pathways and International Consortium for Health Outcomes breast cancer dataset.
In recognition of her sustained career excellence and innovation, Christobel has been publicly acknowledged through numerous awards and honours including Order of Australia 2018, the Uccio Querci della Rovere Award (2018), WA Women’s Hall of Fame Inductee (2018), WA Scientist of the Year (2017) and Cancer Council WA career Achievement Award (2021), and was elected to the Australian Academy of Health and Medical Science in 2016. She has performed research for >30 years evaluating the efficacy and utility of therapy for early breast cancer.
In the past five years, Christobel has published over 200 peer-reviewed journal articles (two in The Lancet), two book chapters and one book. She sits on the boards of a number of health and research organisations including as Vice-President for All.can International and on the boards of All.can Australia, Breast Cancer Trials, the Australian Centre for Value Based Health Care and PathWest. Christobel is closely involved in strategic planning and management of health and cancer services in Australia including being on the Medicare Review Advisory Committee, past President of Breast Surgical Society of ANZ, and past Advisory Council member of Cancer Australia. She led the first WA cancer framework and has advised state and federal governments on cancer for nearly 20 years, as well as contributing to cancer policy in developing countries (Bhutan and Timor L’Este).
Photo taken from:https://findanexpert.unimelb.edu.au/profile/916191-christobel-saunders
Andy Redfern is Associate Professor of Medical Oncology at the University of Western Australia, Associate Director for Clinical Strategy at Harry Perkins Institute of Medical Research, Consultant Medical Oncologist at the Fiona Stanley Hospital, Perth, and Medical Director of Linear Clinical Research specialising in early phase human trials.
Beyond a clinical practice treating breast and urological cancers, Andy is principal investigator for a range of clinical trials across all phases and has a portfolio of translational research initiatives. His research interests centre around growth signalling and mechanisms of chemotherapy and hormone therapy resistance in cancer, differentiation and EMT in cancer progression, tumour-stroma interactions and Indigenous cancer biology.
Andy is also chairman and lead clinician of the State Breast Cancer Collaborative and is on scientific advisory boards for the Cancer Council of Western Australia and the Australasian Breast Cancer Trials Group.
Photo taken from: https://research-repository.uwa.edu.au/en/persons/andrew-redfern
Dr Richard De Boer is a Melbourne-based medical oncologist who treats people with breast and lung cancer. He is a compassionate communicator and will devise treatment plans to realise the best possible outcome.
Dr Richard De Boer is an accomplished medical oncologist with primary interests in breast and lung cancer. His breast cancer interest focus is on endocrine therapy and mechanisms of resistance, and treatment-induced bone loss and bone metastases.
Richard completed his general medical training and then medical oncology training at the Royal Melbourne Hospital. In 1997 he undertook a three year breast and lung cancer clinical research Fellowship at the Royal Marsden Hospital in London. He returned to Melbourne in 2000 and since then has been a consultant medical oncologist working in both public and private practice.
Richard is actively involved in clinical research, and is the principal investigator in both local and international studies.
A/Prof Nicole McCarthy obtained her medical degree through the University of Queensland in 1990. She underwent her internal medicine and medical oncology training in Brisbane and was awarded her Fellowship of the Royal Australasian College of Physicians in 1998. To further advance her academic career, A/Prof McCarthy joined the National Cancer Institute (Bethesda, MD, USA) Medical Oncology Fellowship program from 1998 – 2001. During her fellowship her main interests included clinical trials and translational research investigating new drug treatments for breast cancer, in particular inflammatory breast cancer and anti-angiogenesis agents. She also completed a Masters in Health Sciences in Clinical Research through Duke University and her thesis focused on autologous stem cell transplant and immune reconstitution in patients with metastatic breast cancer.
A/Prof McCarthy spent two years in Auckland and was the recipient of the Breast Cancer Research Trust Fellowship Grant. A/Prof McCarthy returned to Brisbane in January 2006 and has remained focused on clinical trials research. A/Prof McCarthy is the Chair of the Breast Cancer Trials Medical Oncology Craft Group and is a member of their Scientific Advisory Committee. Her other clinical and research interests include management of gynaecological cancers and sarcomas. A/Prof McCarthy sits on a number of national advisory boards and guideline groups and has a close involvement with several breast cancer consumer groups including the Kim Walter’s Choices Program and the Breast Cancer Network of Australia.
A/Prof McCarthy’s work has been published in leading journals and she is an investigator on several grants including NHMRC and Queensland Cancer Council. Since September 2009, A/Prof McCarthy has held a position as Associate Professor in Medicine with the University of Queensland.
Information taken from: https://iconcancercentre.com.au/doctor/nicole-mccarthy/